Rituximab in myositis: where are we now? A survey of current usage.

"Disclosure statement : D.I. has consulted for Merck Serono, Eli Lilly, AstraZeneca, Servier and Immupharma. The honoraria offered are passed onto a local arthritis charity. The other authors have declared no conflicts of interest."

"Funding No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. Disclosure statement: D.I. has consulted for Merck Serono, Eli Lilly, AstraZeneca, Servier and Immupharma. The honoraria offered are passed onto a local arthritis charity. The other authors have declared no conflicts of interest. Ethics: The Declaration of Helsinki was followed throughout the period in which we have taken care of the patients described."